Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $170,047.26 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 1,822 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $170,047.26. Following the completion of the sale, the insider directly owned 12,817 shares of the company’s stock, valued at approximately $1,196,210.61. This trade represents a 12.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Joanne Quan also recently made the following trade(s):

• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97.

Mirum Pharmaceuticals Trading Down 1.8%

MIRM traded down $1.74 during trading hours on Friday, reaching $94.29. The company’s stock had a trading volume of 802,708 shares, compared to its average volume of 890,067. The stock has a market cap of $4.85 billion, a PE ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $96.84. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The business’s 50-day moving average is $76.87 and its 200-day moving average is $70.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter last year, the firm earned ($0.30) earnings per share. The firm’s quarterly revenue was up 47.1% compared to the same quarter last year. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on MIRM. Evercore ISI reaffirmed an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Stifel Nicolaus upped their price objective on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, January 12th. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.58.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Emerald Advisers LLC boosted its position in shares of Mirum Pharmaceuticals by 20.9% in the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock valued at $27,095,000 after purchasing an additional 63,834 shares during the period. Jump Financial LLC increased its position in Mirum Pharmaceuticals by 839.7% during the second quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock worth $7,567,000 after buying an additional 132,866 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $1,728,000. Eventide Asset Management LLC boosted its holdings in shares of Mirum Pharmaceuticals by 4.4% in the second quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after acquiring an additional 110,485 shares during the period. Finally, Emerald Mutual Fund Advisers Trust acquired a new stake in shares of Mirum Pharmaceuticals in the second quarter valued at approximately $11,071,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.